Immuron Ltd — Regulatory Filings 2009

Sep 20, 2009

==> picture [192 x 41] intentionally omitted <==

21 September 2009

The Manager The Company Announcement Office Australian Stock Exchange Sydney NSW

Dear Sir

Completion of recruitment of HIV trial

Immuron Limited (ASX: IMC; OTCQX: IMROY) would like to update shareholders about the completion of recruitment for a multicentre HIV adjunct therapy trial in Australia.

Immuron has an antibody-based ‘Bioguard’ formulation currently in human trials to investigate its efficacy in helping control the abnormal gastrointestinal inflammation associated HIV (Human Immunodeficiency Virus) infections. It is believed that this formulation will slow progress of the disease when used either alone or in combination with an anti-retroviral drug.

The Australian based study (“CORAL”) is a multicenter trial sponsored by the internationally recognised National Centre for HIV Epidemiology and Clinical Research of the University of New South Wales.

The site trial running at multiple sites throughout Australia has now completed its full recruitment of volunteers.

Professor Colin Chapman, Immuron Executive Chairman is pleased to see this significant milestone. “The end of the recruiting phase is often a very difficult phase and is quite significant. As clinical trials are planned around the treatment length for each individual, once the last volunteer is on the program the endpoint of the trial can be reliably predicted.”

The results from this trial are scheduled for release in mid 2010.

Yours faithfully

==> picture [138 x 72] intentionally omitted <==

Professor Colin Chapman Executive Chairman Immuron Limited

ABN 80 063 114 045 Level 1, 39 Leveson Street North Melbourne VIC 3051 AUSTRALIA

Tel (61) 3 9018 4880 Fax (61) 3 9018 4881

www.immuron.com